Ketim Therapeutics Announces the Appointment of Dr. Maciej Trzaskowski as Chief Scientific Officer
Ketim Therapeutics Appoints Dr. Maciej Trzaskowski as Chief Scientific Officer to Lead AI-Driven Biomarker Research and Precision Therapeutics
Ketim Therapeutics, a pioneering company focused on advancing blood-based biomarker screening and mental health diagnostics, is delighted to announce the appointment of Dr. Maciej Trzaskowski, PhD as its new Chief Scientific Officer (CSO) and Co-Founder of Ketim Therapeutics.
Dr. Trzaskowski joins Ketim with over 15 years of experience in statistical genetics, bioinformatics, and artificial intelligence. His diverse expertise and leadership in developing AI-powered analytics for health applications uniquely position him to drive Ketim’s mission of transforming perinatal mental health screening and therapeutic innovation.
An Exceptional Track Record of Scientific Excellence
Dr. Trzaskowski's extensive career includes significant contributions to the fields of genomics, machine learning, and complex AI models. As the Founder of InteliMagik and Co-Founder of Profenso, he has a proven track record of building AI automation platforms to solve complex healthcare challenges.
Prior to his entrepreneurial ventures, Maciej served as Head of Research at Max Kelsen, a leading AI and data science firm, where he played a pivotal role in the company’s growth prior to its acquisition by Bain & Company. He also holds prominent academic positions as an Adjunct Senior Fellow at the University of Queensland and a Visiting Scientist at QIMR Berghofer and QUT, and is an Associate Investigator at the ARC Centre of Excellence for Information Resilience. In the UK, he held the title of The British Academy Fellow aiming to improve utilisation of polygenic risk prediction in large population samples. His experience goes beyond Kings College London, where he acquired extensive training in AI techniques such as Machine Learning and Multi-Agent Systems, with a specific focus on Agent Based Modelling, at University of Washington, Seattle, and at the Department of Mathematics and Natural Sciences, King's College London. He has an impressive H-index: 50 with over 15,000 citations.
Dr. Trzaskowski's contributions to scientific research have been widely recognized, with an H-index of 50 and over 15,000 citations. His research spans multiple health domains, including cancer, ophthalmology, and psychiatry, and he has been actively involved in polygenic risk prediction to better understand genetic influences on disease outcomes.
Driving Ketim’s Vision Forward
Dr. Trzaskowski has already been collaborating closely with Ketim Therapeutics over the past several months in stealth mode, leading efforts to develop an innovative AI/ML-based biomarker pipeline. His appointment as CSO marks the beginning of a new chapter for Ketim, focusing on using AI models for biomarker discovery and drug development.
“Welcoming Maciej as our CSO is a significant milestone for Ketim Therapeutics,” said Dr. Clarissa Yates, CEO and Founder. “His unparalleled expertise in statistical genetics, machine learning, and bioinformatics will propel Ketim forward as we expand our capabilities in predictive analytics and precision medicine. Together, we aim to revolutionize mental health diagnostics and therapeutics, starting with our flagship project in perinatal mental health.”
Dr. Trzaskowski shared his excitement about joining Ketim: “I am thrilled to officially become part of the Ketim team. This is a rare opportunity to apply cutting-edge AI techniques to a field that has significant unmet needs. By leveraging biomarkers and machine learning, we have the potential to reshape the landscape of mental health screening and treatment.”
About Ketim Therapeutics
Founded in 2024, Ketim Therapeutics is a Brisbane-based company dedicated to transforming maternal mental health by harnessing the power of blood-based biomarkers for early screening and therapeutic innovation. By integrating innovative technologies and predictive diagnostics, Ketim Therapeutics is committed to improving outcomes for women and families, providing accessible, personalised solutions to maternal mental health challenges.
For media inquiries, please contact:
Dr. Clarissa Yates
CEO, Ketim Therapeutics
Email: clarissa.yates@ketim.com.au
